Loading... Please wait...

Categories

Our Newsletter


PF-2341066 (Crizotinib) | cMet/ALK inhibitor

PF-2341066 (Crizotinib).jpg
  • PF-2341066 (Crizotinib).jpg
  • PF-2341066 (Crizotinib), 400x400px, png
Price:
$109.00
SKU:
C7234-5
Quantity:
Buy in bulk and save

Product Description

PF-2341066 (Crizotinib) is an orally-available, ATP-competitive, aminopyridine-based dual inhibitor of c-Met and ALK with IC50 of 11 nM and 24 nM, respectively. [1] A kinase selectivity panel shows that PF-2341066 is selective against most tyrosine and serine-threonine kinases, with modest activity with Ron (IC50, 80 nM). [2] PF-2341066 inhibits c-Met phosphorylation and c-Met-dependent proliferation, migration, and invasion of human tumor cells in vitro at IC50s of 5 to 20 nM.

PF-2341066 has been shown to be effective in osteosarcoma growth [3] and anaplastic large-cell lymphomas [4].

Technical information:

Chemical Formula:   C21H22Cl2FN5O
CAS #:   877399-52-5
Molecular Weight:   450.34
Purity:   >99%
Appearance:   White
Chemical Name:   3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine
Solubility:   Up to 40 mM in DMSO
Synonyms:   Crizotinib, PF-02341066, PF-2341066, PF 2341066, PF2341066

Shipping Condition: The product is shipped in a glass vial at ambient temperature.
Storage condition: For longer shelf life, store solid powder at 4oC desiccated, or store DMSO solution at -20oC.

Reference:

1. Zou et al., An orally available small-molecule inhibitor of c-Met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms. Cancer Res. 2007, 67, 4408-4417. Pubmed ID: 17483355
2. Cui et al., Structure based drug design of crizotinib (PF-02341066), a potent and selective dual inhibitor of mesenchymal-epithelial transition factor (c-MET) kinase and anaplastic lymphoma kinase (ALK). J. Med. Chem. 2011, 54, 6342-6363. Pubmed ID: 21812414
3. Sampson et al., The orally bioavailable met inhibitor PF-2341066 inhibits osteosarcoma growth and osteolysis/matrix production in a xenograft model. J. Bone. Miner. Res. 2011, 26(6), 1283-1294. Pubmed ID: 21308771
4. Christensen et al., Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma. Mol. Cancer Ther. 2007, 6, 3314-3322. Pubmed ID: 21812414

Other Information:

Product Specification (pdf)
MSDS (pdf)
Certificate of Analysis is available upon request.

Write your own product review

Product Reviews

This product hasn't received any reviews yet. Be the first to review this product!

Add to Wish List

Click the button below to add the PF-2341066 (Crizotinib) | cMet/ALK inhibitor to your wish list.

You Recently Viewed...